Another study analyzed 81 patients with unresectable CRC treated with 5-FU-based regimens and demonstrated that the loss of BNIP3 expression in cancer cells increased resistance to 5-FU-based drugs and worsened prognosis. The gene discussed is BNIP3; the disease is colorectal carcinoma.